Spruce Biosciences, Inc. (SPRB)

Market Cap	86.28M
Revenue (ttm)	n/a
Net Income (ttm)	-46.18M
Shares Out	39.75M
EPS (ttm)	-1.96
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	25,852
Open	2.19
Previous Close	2.14
Day's Range	2.14 - 2.20
52-Week Range	0.96 - 3.57
Beta	2.33
Analysts	Buy
Price Target	7.14 (+226.77%)
Earnings Date	May 10, 2023

About SPRB

Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for adult patients suffering from congenital adrenal hyperplasia (CAH), which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction and clinical consequences in adult patients with classic CAH that is Phase 2b clinical trial. It is also developing tildacerfont for...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Oct 9, 2020
• Employees: 22
• Stock Exchange: NASDAQ
• Ticker Symbol: SPRB

Analyst Forecast

According to 13 analysts, the average rating for SPRB stock is "Buy." The 12-month stock price forecast is $7.14, which is an increase of 226.77% from the latest price.

Price Target

$7.14

(226.77% upside)

Analyst Consensus: Buy